Complex EVAR in Inflammatory and Infective Abdominal and Thoracoabdominal Aortic Aneurysms
Launched by CEVARII · Apr 20, 2024
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Infective Native and Inflammatory Aortic Aneurysms (INAA \& IAA) are rare, morbid conditions with unique challenges. INAA \& IAA share clinical and imaging similarities but differ significantly in pathophysiology, management, and prognosis. Open surgical repair of INAA \& IAA is technically challenging and associated with higher complications.
Complex endovascular aortic repair in inflammatory and infective perivisceral abdominal aortic aneurysms and thoracoabdominal aortic aneurysms (CEVARII) study is a collaborative international consortium effort among vascular surgeons to establish a d...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients aged ≥ 18 years old with a diagnosis of inflammatory abdominal aortic aneurysm (IAA) or infective native aortic aneurysms (INAA), who have undergone complex endovascular aortic repair (cEVAR) are eligible for inclusion in this study.
- Exclusion Criteria:
- • Suboptimal documentation of clinical, laboratory, and imaging findings
- • Presence of prosthetic material (endograft or open graft material)
- • Prior open or endovascular aortic repair
- • Findings suspicious of secondary aorto-enteric or -bronchial fistulas.
About Cevarii
Cevarii is a pioneering clinical trial sponsor dedicated to advancing innovative healthcare solutions through rigorous research and development. With a focus on enhancing patient outcomes, Cevarii collaborates with healthcare professionals and research institutions to design and implement clinical trials that adhere to the highest ethical and scientific standards. The organization leverages cutting-edge technology and a patient-centric approach to streamline trial processes, ensuring efficiency and integrity while fostering a commitment to transparency and collaboration within the scientific community. Cevarii aims to contribute significantly to the development of transformative therapies that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Aurora, Colorado, United States
Patients applied
Trial Officials
MEL J Sharafuddin, MD
Principal Investigator
Memorial Hospital Central, University of Colorado Healthcare
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported